Abstract Squamous cell carcinoma of the anus (SCCA) is a rare disease in the average population but is an increasing concern among immunocompromised individuals, such as the HIV-seropositive. Coinfection with human papillomavirus (HPV) in this population is common. HPV infection is difficult to clear with a compromised immune system, which results in a greater risk of tumor development and a more aggressive progression of the disease. The recent approval of a prophylactic HPV vaccine for cervical cancer has sparked an interest in a search for improved immunotherapeutic multimodality therapies to combat anogenital tumors associated with the virus. In this review, we discuss the known mechanisms of action of HIVassociated SCCA, examine the current treatments for the disease, and focus on the potential of an immunotherapeutic vaccine approach for both prophylactic and therapeutic application.
Introduction
Squamous cell carcinoma of the anus (SCCA) is an uncommon malignancy that represents 1.5% of all gastrointestinal cancers in the United States, accounting for only 3,400 cases per year [1] [2] [3] . During the last few decades, a marked increase in the incidence of anal cancer has been observed in both men (93%) and women (48%) [1] . This increase is even more marked for immunosuppressed patients [1, 4] . Although anal carcinoma is rare in the average population, it has an increased prevalence among homosexuals, immunosuppressed patients, and those seropositive for human immunodeficiency virus (HIV) infection. The risk of SCCA is 120 times higher in HIVpositive individuals than in the rest of the population, making anal carcinoma the fourth most commonly reported malignancy among men with HIV infection [5, 6] . In this report, we will summarize the current understanding of SCCA, the relationship of HIV to human papillomavirus (HPV)-associated SCCA, treatment of immunocompetent and immunocompromised patients, and vaccine candidates and immunotherapy for SCCA.
Current understanding of SCCA
SCCA tumors begin in the squamous cells that line the lower part of the anus and the majority of the anal canal. They are classified topographically according to the anatomy of the canal's three zones: upper, middle, and lower parts, which are covered with rectal-type mucosa, anal transitional zone mucosa, and partly keratinized squamous epithelial cells, respectively. Upper and middle region tumors are known as anal canal lesions, and lower region tumors are known as anal margin tumors and perianal lesions [7] . Anal cancers are further subdivided into various histological variants. Tumors have a predilection for the transformation zone, the transition site from the cylindrical to squamous epithelium of the anus, which makes squamous cell carcinoma the most common variant [8] .
The pathogenesis of anal cancer is poorly understood; however, many factors are known to be important in the development of the disease, including smoking, initiation of sexual life at an early age, having a large number of children, and the use of oral contraceptives for an extended time [9] [10] [11] . Viruses also have been implicated in the development of anal cancer. Among patients without a history of genital warts, for example, a history of seropositivity for herpes simplex virus type 2 (HSV-2) has been found to be associated with anal cancer [12] . Whereas HSV and other viruses, such as cytomegalovirus (CMV) and Epstein-Barr virus (EBV), have been investigated as potential agents [12] , SCCA is most strongly associated with human papillomavirus (HPV) infection, a feature, among others, that SCCA shares with cervical carcinoma [5] . The establishment of a persistent HPV infection is thought to be central to the development of the majority of cases of cervical cancer, because more than 95% of cervical tumor specimens harbor HPV DNA [13] . The results from a series of epidemiologic studies conclude that HPV infection is central to anal cancer development as well [2, 14] . In fact, the presence of HPV DNA in SCCAs is so high (ranging in the literature 35-60%) [15] , it suggests that HPV presence may be a necessary cause for squamous cell carcinomas of the anal canal [16] .
HPV are small, nonenveloped, double-stranded DNA viruses that infect skin or mucosal tissue and are associated with a variety of clinical conditions ranging from innocuous lesions to cancer [17] . HPV infection is the most common sexually transmitted infection among sexually active couples, with an annual incidence of approximately 5.5-6.2 million. An estimated 75% of sexually active men and women have been exposed to HPV at some point in their lives [18] . HPV are subdivided into types based on their genome sequences, with each type identified by number. Each HPV type occurs in the form of variants, differentiated by approximately 2% nucleotide differences in most genes and 5% in less conserved regions [19] . More than 100 HPV types have been identified to date.
The considerable variation present in the HPV genome results in variations in the strength of the association of different HPV types with different types of cancer [13] . Infection with many of these subtypes can lead to premalignant transformation of squamous epithelial cells [14] , resulting in high-grade squamous intraepithelial lesions and invasive squamous cell carcinoma [20] . HPV-16 and -18 account for approximately 70% of cancers of the cervix, vagina, and anus, and 30-40% of cancers of the vulva, penis, and orophaynx [21] . HPV-16 has been shown to be present in the majority of anal cancers using PCR identification techniques [22, 23] . In many cases, infection is not limited to one subtype; in fact, infection with multiple HPV types is common among patients with anal cancer. It is unclear whether multiple subtype infections are associated with a higher risk of malignancy or a more rapid rate of progression [9] .
It is known that oncogenic strains of HPV (primarily HPV-16 and -18) integrate into the host cell's DNA and cause progression from the normal epithelium to carcinoma. They are thought to alter cell cycle control, causing chromosomal instability [24] . However, the exact mechanism of HPV-induced malignant transformation has not been determined, and may be different in HIV-negative and HIV-positive patients [25] . High-risk HPV types encode for three oncoproteins with growth-stimulating and transforming properties: E5, E6, and E7 [26] . Evidence points to a critical role for the HPV E6 and E7 genes; high-grade squamous intraepithelial lesions have higher levels of expression of these particular proteins than do low-grade lesions. In addition, continued expression of both of these proteins is required for maintenance of the malignant state [23, 27] , and keratinocyte transformation has been shown to require E6 or E7 protein expression [27] . It also is likely that variations in the E6 gene sequence may allow evasion from the host immune system, which would result in increased viral persistence [28] . A mechanistic possibility is that HPV induces high-grade dysplasia by integrating into host DNA and/or inhibiting the p53 protein, possibly through the interaction of E6 proteins with host factor E6AP ubiquitin ligase, binding p53 and causing its degradation [15] . The p53 gene is frequently wild-type in HPVrelated cervical cancers, and the same is likely in SCCA. It is therefore likely that E6-mediated abrogation of p53 protein-dependent apoptosis has the equivalent effect to inactivating mutations of the p53 gene [26] . In addition, Hiller et al. [29] recently stated that several variants of HPV E6 protein may play a role in supporting increased viral persistence by avoiding immune responses.
E7 oncoprotein binds and degrades the retinoblastoma tumor suppressor protein (pRB), as well as additional targets, including cyclin-independent kinase inhibitors and several transcription regulators [30] . By inhibiting the functions of both E6 and E7 proteins with antisense mRNA, Hu et al. [31] were able to convert HPV-transformed cells back to the normal phenotype. E6 and E7 thus represent potential therapeutic targets. A more detailed understanding of the mechanisms of transformation and progression of SCCA is needed, in particular in light of evidence indicating possible alternate pathways in HIVinfected individuals [26] .
Relationship of HIV to HPV-associated SCCA HIV and HPV coinfected patients are at high risk of developing precancerous anal lesions and anogenital cancers [4, 32] . The incidence of invasive anal cancer is 120 times higher in HIV-infected patients than in the general population and is significantly increased in AIDS patients as well [21, 33] . HIV increases the relative risk of anal carcinoma by 1.7 in women and 3.1 in men [4] , particularly in the decade from 5 years before to 5 years after AIDS, compounded by more frequent relapses and a longer median time to cure after treatment [34] .
Anal cancer is preceded by high-grade squamous intraepithelial neoplasias, otherwise known as Bowen's disease [12, 26, 35] . HIV-positive patients with perianal Bowen's disease are more likely to progress from low-grade to highgrade SCCA within a given time period, compared with HIV-negative individuals, and can subsequently progress to invasive SCCA within a short period despite multiple therapies [36, 37] .
It is thought that HIV increases the activity and duration of HPV infection, due to the ineffectiveness in clearing the infection in immunocompromised patients, thus leading to an increase in anal carcinoma and the aggressiveness of the tumors [1, 38, 39] . HPV infection is transient in immunocompetent individuals, with an average duration of 8 months followed by spontaneous clearance by humoral and cellular immune responses against viral antigens [18, 40] . HIV-positive patients, on the other hand, have persistent HPV infection in the anal canal, which promotes a high rate of persistent shedding of HPV particles. This persistent shedding is considered critical in the development of intraepithelial neoplasia, particularly in HIVpositive women [40, 41] . Prolonged HPV also may result in the reactivation of previously acquired HPV infection, and a subsequent loss of control of HPV viral replication [4] .
In addition, several other factors come into play: HIV-1 tat seems to potentiate expression of E6 and E7 [42] ; the increase in Langerhans cells in the anal mucosa, which is normally seen during HPV infection, is absent in HIVpositive patients, which may favor increased propagation of SCCA [43] ; and HIV alters dendritic cells, which are involved in early presentation of antigens for lymphocytes [44] . The prevalent HPV relapses in immunosuppressed populations also are a likely result of an HIV-mediated altered immune state, as evidenced by the increased prevalence of HPV and decreased CD4 count seen with prolonged HIV infection [39] .
The reason for the relatively recent increase in SCCA among immunosuppressed individuals is most likely due to the advent of treatment with highly active anti-retroviral therapy (HAART). Although the medications included in this therapy do not cure HIV infection, they allow the immune system to reconstitute and have led to a dramatic reduction in mortality and to decreased morbidity [45] . In HIV-negative individuals, HPV-associated anal cancer has a latency period of 5 to 40 years. Although it is thought that immunosuppression may accelerate the development of the malignancy, a similarly long latency period is still observed in HIV-positive patients [46] . HAART has reduced the prevalence of opportunistic infections, and as a result patients are living longer. The longer life expectancy of HAART patients correlates with an increased opportunity for invasive anal carcinoma to develop [4, 46, 47] . In addition, evidence shows that despite HAART-mediated immunoreconstitution, this therapy seems to have limited impact on the development of HPV-related lesions, which is consistent with an increase in lesion prevalence with extended time [48] .
Treatment of SCCA in immunocompetent and immunocompromised patients
Three decades ago the primary treatment for SCCA was abdominoperineal resection (APR) with resultant colostomy [8] . APR involves removal of the anus, the rectum, and part of the sigmoid colon along with their draining lymph nodes, through incisions made in the abdomen and perineum [49] . APR remains an often-used salvage procedure for treatment. However, the introduction of the Nigro protocol in 1974 began a transition toward nonsurgical treatment of SCCA [50, 51] . Nigro et al. pioneered the use of a combined neoadjuvant therapy for anal cancer using fluorouracil, mitomycin, and radiotherapy [50, 52] . Since then, sphincter-preserving approaches, such as chemotherapy and radiation treatments have gradually become the standard treatment [8, 51] , and the need for radical colostomy surgeries has decreased.
Chemoradiotherapy (CRT)-the combined treatment of radiotherapy and chemotherapy-has been proven effective since the early 1990s and is still advocated as a reasonable treatment, resulting in 5-year overall survival and colostomy-free survival rates of 50-78% and 61-76%, respectively [53] . CRT has replaced radical surgery and separate chemo and radiotherapy treatments as the initial treatment of choice for SCCA [47, [53] [54] [55] . It improves local control and has resulted in colostomy-free and even disease-free survival in large tumors [56] . However, this therapy has toxic side effects, such as nausea, diarrhea, anal ulcers, and other chronic effects. Eighteen percent of patients in one study experienced acute grade hematologic toxicity [57] , and even short-term toxicity is always a concern, because this requires patients to take breaks from radiation treatments [58] . Some improvements in toxicity have resulted from the effective progression from the Nigro protocol, which used the addition of mitomycin C (MMC) to 5-fluorouracil (5-FU) and radiotherapy [50] to the less toxic combination of combined modality therapy with external beam radiation, cisplatin, and 5-FU [59] . Cisplatin is an effective substitute for MMC, resulting in favorable long-term survival without as many toxic effects [60] . Even with the toxicity issues, chemoradiotherapy as a treatment has been shown to be comparable to conventional APR [49, 53] as far as overall patient survival rates are concerned, allowing surgical resection to be used solely as a salvage treatment. Although a multimodality treatment (defined as local excision followed by chemoradiotherapy) [49] has improved the outlook for patients who might previously have had only the radical surgery option, there is still much room for improvement in the treatment of SCCA [47] . Several approaches have been attempted to improve treatment results, such as dose intensification of different ratios of chemotherapy and radiotherapy. One approach has been to combine neoadjuvant chemotherapy followed by concomitant radiotherapy-chemotherapy, with the goal that the initial induction chemotherapy may reduce tumor bulk before the concurrent chemoradiation treatment, which would allow for improvement of local oxygenation and result in a higher probability of local control after irradiation [61] . Salama et al. [52] recently studied an approach using concurrent chemotherapy and intensitymodulated radiation therapy, and the results suggested favorable tolerance of toxicity levels. However, minor improvements have not yet yielded an ideal therapeutic scheme. Even after chemotherapy and radiotherapy treatments, complications and local treatment failure often result in the need for APR in approximately one-third of patients [62] . In these cases, the outlook is grim, because salvage surgery of this kind is associated with significant morbidity, with long-term survival achieved in only 39% of patients [63] .
Whereas chemoradiation rapidly became the standard treatment for SCCA for immunocompetent patients, many clinicians were wary of adopting this approach in HIV seropositive patients [55] . This resistance was based on reports of considerable levels of toxicity for these patients in the past, which found differences in diagnostic, therapeutic, and prognostic results between HIV-positive and HIV-negative patients [64] . Recent studies have demonstrated that with the advent of the HAART era, toxicity and treatment outcomes of chemoirradiation are similar [14, 47, 55, 65] . Thus, chemoradiotherapy has become standard treatment for immunocompromised and immunocompetent patients [66] .
The current view is that patients with CD4 ? T cell counts [200/lmol, particularly those receiving HAART, should have their cancers managed in the same manner as their HIV-negative counterparts; treatment should not be withheld based on HIV status [65] [66] [67] . A recent study by Chiao et al. [65] revealed that in cases in which there were no differences between the receipt of treatment for HIVpositive and HIV-negative patients, the survival rate was the same for both groups. The 2-year observed survival rates were 77% and 75% among HIV-positive and HIVnegative individuals, respectively. In multivariate Cox analysis, significant predictors of survival were age, sex, metastasis at diagnosis, and comorbidity score, whereas HIV infection did not affect survival.
However, in patients with CD4 ? T cell counts \200/ lmol, claims that HIV-positive patients experience greater toxicity to chemoradiation treatments may be warranted. Studies have found that these patients need longer treatment breaks and dose reductions as a result of the increased toxicity, making them more susceptible to recurrences and requiring modification of treatment regimes [3, 31] . The value of combined modality in AIDS patients and those who are in advanced stages of the disease is questionable [56] .
As with all cancers, prevention is key, and the higher rate of SCCA observed in HIV-positive patients should be an indication that additional preventative screening is necessary. Using cervical cancer prevention as a paradigm, anal Pap smear screening, high-resolution anoscopy, colposcopy, and other screening methods have been proposed as part of routine HIV preventive care to detect precancerous anal lesions in the hope of decreasing anal cancer rates [10, 14, 48, [67] [68] [69] [70] . One study demonstrated that screening as part of routine HIV care revealed cytologic abnormalities in patients without obvious risk factors, suggesting that anal cancer screening should be performed on all HIV-infected patients, regardless of sex or HIV risk factors, and not just those with decreased T-cell counts or chronic inflammation as is common [71] .
Vaccine candidates and immunotherapy
The most effective methods currently available for treating invasive anal carcinoma in HIV patients have uncertain outcomes, making successful regimens for treatment of the disease difficult to implement [72] . Currently the campaign for more effective treatment of SCCA involves observing patients with premalignant lesions with the intent to detect and destroy early invasive lesions. The standard treatment after screening has been surgical resection or laser ablation, followed by CRT once the neoplasia becomes widespread [73] . However, dysplasia has been difficult to eradicate with these current treatments and has a high level of recurrence, particularly among the HIV population [74] . New treatment options are clearly needed. The current consensus for cancer treatments is that an immunological strategy needs to be combined with chemotherapy and radiotherapy in an expanded multimodality combination treatment to the greatest effect on the reduction or elimination of tumor cells [75] . Thus, there has been a recent drive for immunotherapeutic strategies that establish a balance between antitumor activity, reduction of side effects, and low levels of recurrence.
The search for an immunotherapeutic approach in recent years has led to a milestone in the field of cervical cancer, with the development of the first approved HPV vaccine. The HPV vaccine is a quadrivalent vaccine that consists of recombinant viral-like particles (VLPs) of four HPV subtypes mixed with an aluminum-containing adjuvant [32] . HPV VLPs can be generated by synthesis and self-assembly in vitro of the major virus capsid protein L1 [76] , a protein expressed during productive HPV infection. HPV L1 VLPs are practically identical to native virions from a morphological and antigenic standpoint, a feature that has allowed the technology to be exploited to produce subunit vaccines, which elicit high titers of anti-L1 VLP antibodies [76] . The four subtypes of HPV found in the quadrivalent subunit vaccine include HPV-16 and -18, which cause 70% of cervical cancers, and HPV-6 and -11, which cause approximately 90% of genital warts, thus allowing the HPV vaccine to prevent most genital warts and most cases of cervical cancer [77] . The close association of SCCA with HPV indicates that SCCA may be a good candidate for an anti-HPV prophylactic vaccination strategy.
The quadrivalent HPV vaccine has been a great step forward in the search for cancer immunotherapy in general and may have a direct impact on the treatment of SCCA. A phase III clinical trial was conducted to evaluate the efficacy of a prophylactic quadrivalent vaccine in preventing anogenital diseases associated with HPV-6, -11, -16, and -18 [78] . The quadrivalent vaccine significantly reduced the incidence of HPV-associated anogenital diseases in young women [79] , and therefore has the potential to be used successfully against SCCA.
One drawback of this vaccine in its current form is that it is only useful from a preventative standpoint and cannot be used to clear a preexisting infection, nor can it prevent an infection with a different type of HPV [80, 81] . Thus, the search continues for an antigen that would allow for an effective vaccine against SCCA that may act both as a preventative and therapeutic vaccine. The method of creating VLP-based vaccines should theoretically be expandable to additional antigenic molecules that may fit these criteria, and the approach can be applied to chimeric VLP vaccines against HIV-associated SCCA. The challenge is to find an antigenic molecule that would elicit an effective immune response. Although VLP vaccines have shown prophylactic efficacy, their therapeutic potential is limited by the absence of capsid gene expression in tumors [82] .
The viral oncogenes E6 and E7 of high-risk HPV types, such as HPV-16 and -18 are regularly expressed in anogenital precancerous lesions and cancers, and make for potential candidates for immunization [42] . Thus, there is a clear interest in immunotherapy via therapeutic vaccination against these gene products, and multiple methods are being studied for effective treatments. Ohlschlager et al. [83] tested naked DNA containing a modified HPV-16 E7 for immunization against cervical cancer and found that it induced an E7 wild-type-specific T-cell response. Klencke et al. [73] examined the feasibility of using an agent containing a segment of HPV-16 E7 protein toward induction of an immune response against E7. However, this was a phase I trial designed to test safety, and thus the effectiveness of the treatment must be properly evaluated in future trial progressions. A successful phase II clinical trial was recently conducted by using a vaccinia virus MVA E2 recombinant vaccine, which showed a successful regression of high-grade lesions in female patients [84] . More recently, Kaufmann et al. [85] combined the immunotherapeutic effects of L1 and E7 proteins in a chimeric VLP vaccine trial. The chimeric molecules were able to induce L1 and E7-specific T lymphocytes. The vaccination also resulted in the induction of new B-cell clones, and a good safety profile was established. L2E7E6 chimeric vaccines also are being tested to neutralize HPV infection [82] . Future studies are needed to demonstrate the efficacy of chimeric molecules against SCCA and the effect that such treatment may have on immunosuppressed patients.
Conclusions
Clearly, immunotherapeutic approaches using E7 proteins, or other yet-to-be identified antigenic molecules, are a promising alternative to the current limited treatments for SCCA. In particular, an antigenic marker might provide a control of intraepithelial lesions at different stages of cancer progression and would make treatment of highgrade dysplasia a possibility. An antigenic molecule that increases an immune response to high-grade intraepithelial precancerous lesions would give surgeons a welcome alternative to current therapeutic methodologies. The advent of microarray technology has allowed for the identification of many genes that are overexpressed in tumor cells of various cancers. Currently, gene expression patterns in pancreatic cancer have been studied using such platforms [86] and will undoubtedly be applied to SCCA tumors in future studies. However, the impact that these vaccines may have on immunosuppressed individuals is undetermined, because little is known of the mechanisms of tumor progression in this population.
